- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post Zymeworks Completes Acquisition of Theravance Biopharma appeared first on Zymeworks.
The post Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA appeared first on Zymeworks.
The post U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma appeared first on Zymeworks.
The post Zymeworks Announces Participation in Upcoming Investor Conferences appeared first on Zymeworks.
The post Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results appeared first on Zymeworks.
The post Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 appeared first on Zymeworks.
The post Zymeworks to Acquire Theravance Biopharma, Inc. appeared first on Zymeworks.
The post Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 appeared first on Zymeworks.
The post BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 appeared first on Zymeworks.
The post Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA appeared first on Zymeworks.